Respiri Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Respiri.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.7%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Respiri Limited's (ASX:RSH) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Respiri no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

ASX:RSH - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2024	1	-7	-7	-7	N/A
3/31/2024	1	-7	-6	-6	N/A
12/31/2023	1	-6	-5	-5	N/A
9/30/2023	1	-6	-5	-5	N/A
6/30/2023	1	-6	-5	-4	N/A
3/31/2023	1	-6	-6	-6	N/A
12/31/2022	1	-6	-8	-8	N/A
9/30/2022	1	-6	-8	-8	N/A
6/30/2022	1	-7	-8	-8	N/A
3/31/2022	1	-7	-7	-7	N/A
12/31/2021	1	-8	-6	-6	N/A
9/30/2021	1	-9	-7	-7	N/A
6/30/2021	1	-11	-7	-7	N/A
3/31/2021	1	-12	-7	-7	N/A
12/31/2020	1	-12	-7	-7	N/A
9/30/2020	2	-10	-6	-6	N/A
6/30/2020	2	-7	-5	-5	N/A
3/31/2020	2	-7	-5	-5	N/A
12/31/2019	2	-7	-6	-6	N/A
9/30/2019	2	-8	-6	-6	N/A
6/30/2019	1	-8	-6	-6	N/A
3/31/2019	1	-7	-5	-5	N/A
12/31/2018	1	-6	-4	-4	N/A
9/30/2018	1	-4	-3	-3	N/A
6/30/2018	1	-3	-2	-2	N/A
3/31/2018	1	-2	N/A	-2	N/A
12/31/2017	2	-1	N/A	-2	N/A
9/30/2017	1	-2	N/A	-2	N/A
6/30/2017	1	-3	N/A	-3	N/A
3/31/2017	1	-3	N/A	-3	N/A
12/31/2016	1	-3	N/A	-3	N/A
9/30/2016	1	-4	N/A	-3	N/A
6/30/2016	1	-4	N/A	-2	N/A
3/31/2016	0	-5	N/A	-3	N/A
12/31/2015	0	-5	N/A	-4	N/A
9/30/2015	0	-5	N/A	-5	N/A
6/30/2015	0	-5	N/A	-6	N/A
3/31/2015	0	-6	N/A	-6	N/A
12/31/2014	0	-6	N/A	-7	N/A
9/30/2014	0	-8	N/A	-8	N/A
6/30/2014	0	-10	N/A	-9	N/A
3/31/2014	0	-10	N/A	-8	N/A
12/31/2013	0	-10	N/A	-8	N/A
9/30/2013	0	-8	N/A	-6	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de RSH es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de RSH crezcan más rápidamente que el mercado Australian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de RSH crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de RSH crezcan más rápidamente que el mercado de Australian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de RSH crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de RSH se prevé que sea elevada dentro de 3 años.

Respiri Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.007 loss in FY 2023)

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

New major risk - Shareholder dilution

New major risk - Share price stability

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 1.6 million.

Respiri Limited Announces Executive Changes

New major risk - Share price stability

Respiri Limited has completed a Follow-on Equity Offering in the amount of AUD 1.3876 million.

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.

Less than half of directors are independent

Respiri Limited's (ASX:RSH) CEO Will Probably Find It Hard To See A Huge Raise This Year

Respiri Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.009 loss in FY 2022)

New major risk - Revenue and earnings growth

New minor risk - Financial data availability

New minor risk - Share price stability

Respiri Limited Appoints Brian Leedman as Non-Executive Director

First half 2023 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in 1H 2022)

Respiri Limited Announces Arkansas Heart Hospital Commences Patients on Wheezo RPM

Respiri Limited Announces Minnesota Lung Center Wheezo Rpm Pilot Program Patient Selection Has Been Finalised and Patient Onboarding Has Successfully Commence

No independent directors

Respiri Announces First Patients Enrolled into Wheezo® Remote Patient Monitoring Programs, Further Validating USA Business Model

Respiri Limited, Annual General Meeting, Nov 15, 2022

Full year 2022 earnings released

We're Keeping An Eye On Respiri's (ASX:RSH) Cash Burn Rate

Respiri Limited Announces Executive Changes

Respiri Limited Announces New £2 Million NIHR-Funded UK Paediatric Asthma Clinical Trial with wheezo

Respiri Limited Appoints Brad Snow as A Non-Executive Director

Respiri Limited Appoints Brad Snow as A Non-Executive Director

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Respiri Limited Announces Resignation of Director of Dr. Thomas Duthy

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Full year 2021 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in FY 2020)

Respiri Limited Announces Wheezo Registered and Approved for Sale in the UK Market

We Think Respiri (ASX:RSH) Can Afford To Drive Business Growth

Insider recently bought AU$95k worth of stock

Respiri (ASX:RSH) Is In A Good Position To Deliver On Growth Plans

Respiri Limited Announces New Partnership with Pharmacy 4 Less Banner Group

Respiri Limited Holds Media Events to Mark the Launch of Wheezo

Respiri Limited, Annual General Meeting, Dec 16, 2020

Respiri Limited Files Additional Patent Application

Respiri Limited Announces A Partnership with Entech Electronics for the Global Supply of the Ground Breaking Wheezo

Respiri Limited to Report Fiscal Year 2020 Results on Aug 25, 2020

Respiri Limited announced that it expects to receive AUD 0.09 million in funding

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento